Category: HypertensionSyndicate content

Vascular Dynamics raises $10m

November 7, 2014 by Val Kennedy

Vascular Dynamics reports raising $10 million out of a hoped-for $23 million funding round for its MobiusHD anti-hypertension implant.

Vascular Dynamics raises $10m

Vascular Dynamics said it raised nearly $10 million from a group of unnamed investors for the hypertension implant it's developing.

The Mountain View, Calif.-based startup reported raising $9.7 million in an offering of stock, warrants and other securities as part of a proposed $22.9 million funding round.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Stealth hypertension startup Sympara Medical raises nearly $6m

October 23, 2014 by Alexander Soule

Sympara Medical quietly secures $5.5 million in funding from a handful of investors as it develops a device to treat hypertension.

Stealth hypertension startup Sympara Medical raises nearly $6m

Stealthy Sympara Medical quietly secured $5.5 million in funding from a handful of investors for the hypertension device it's developing.

San Francisco-based Sympara disclosed the funding in a regulatory filing, after recording $4.3 million with the SEC in 2013.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Ablative Solutions tests infusion ablation catheter as hypertension treatment

October 20, 2014 by Alexander Soule

Ablative Solutions begins testing its infusion ablation catheter as a potential treatment for hypertension.

Ablative Solutions tests infusion ablation catheter as hypertension treatment

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

TCT 2014: Another trial shows no benefit for renal denervation in hypertension

September 17, 2014 by Brad Perriello

Another trial of Medtronic's Symplicity renal denervation device in treating hypertension shows no benefit compared with a sham procedure.

TCT 2014: Another Medtronic trial shows no benefit for renal denervation in hypertension

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

TCT 2014 Roundup

September 15, 2014 by Brad Perriello

A roundup of studies released at the annual Transcatheter Cardiovascular Therapies conference in Washington this week.

TCT 2014 Roundup

Here's a look at some of the news coming out of Washington at the 26th annual Transcatheter Cardiovascular Therapies conference this week:

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Medtronic's renal denervation no better at 1 year, researchers say

September 5, 2014 by Arezu Sarvestani

Medtronic's failed Symplicity HTN-3 renal denervation study doesn't look any better with 12 months of follow-up, according to new results presented at this year's European Society of Cardiology Congress.

Medtronic's renal denervation no better at 1 year, study finds

Renal denervation technologies took another blow this week as 1-year results from Medtronic's (NYSE:MDT) much-lamented Symplicity HTN-3 trial still turned out no signs that the treatment is effective against hypertension.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Renal denervation isn't dead, despite Medtronic trial's failure

September 2, 2014 by Brad Perriello

The failure of Medtronic's Symplicity 3 trial doesn't mean the end of renal denervation in treated resistant hypertension, especially in Europe, but future studies face a high bar set by the Medtronic trial's sham control arm.

Renal denervation isn't dead, despite Medtronic trial's failure

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp